Abstract:Fibrous nanomaterials containing silica, titanium oxide, and carbon nanotubes are notoriously known for their undesirable inflammatory responses and associated toxicities that have been extensively studied in the environmental and occupational toxicology fields. Biopersistance and inflammation of "hard" nanofibers prevent their broader biomedical applications. To utilize the structural benefits of fibrous nanomaterials for functionalization with moieties of therapeutic significance while preventing undesirable immune responses, researchers employ natural biopolymers─RNA and DNA─to design "soft" and biodegradable nanomaterials with controlled immunorecognition. Nucleic acid nanofibers have been shown to be safe and efficacious in applications that do not require their delivery into the cells such as the regulation of blood coagulation. Previous studies demonstrated that unlike traditional therapeutic nucleic acids (e.g., CpG DNA oligonucleotides) nucleic acid nanoparticles (NANPs), when used without a carrier, are not internalized by the immune cells and, as such, do not induce undesirable cytokine responses. In contrast, intracellular delivery of NANPs results in cytokine responses that are dependent on the physicochemical properties of these nanomaterials. However, the structure-activity relationship of innate immune responses to intracellularly delivered fibrous NANPs is poorly understood. Herein, we employ the intracellular delivery of model RNA/DNA nanofibers functionalized with G-quadruplex-based DNA aptamers to investigate how their structural properties influence cytokine responses. We demonstrate that nanofibers' scaffolds delivered to the immune cells using lipofectamine induce interferon response via the cGAS-STING signaling pathway activation and that DNA aptamers incorporation shields the fibers from recognition by cGAS and results in a lower interferon response. This structure-activity relationship study expands the current knowledge base to inform future practical applications of intracellularly delivered NANPs as vaccine adjuvants and immunotherapies.

Regulating immune response using polyvalent nucleic acid-gold nanoparticle conjugates.

Cellular response of polyvalent oligonucleotide-gold nanoparticle conjugates.

Cellular Response of Polyvalent Oligonucleotide−Gold Nanoparticle Conjugates

Manipulating Immune Activation of Macrophages by Tuning the Oligonucleotide Composition of Gold Nanoparticles.

Regulation the Morphology of Cationized Gold Nanoparticles for Effective Gene Delivery.

Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation

Gene Regulation with Polyvalent siRNA-Nanoparticle Conjugates*

Self-assembly of poly-adenine-tailed CpG oligonucleotide-gold nanoparticle nanoconjugates with immunostimulatory activity.

Smaller CpG-Conjugated Gold Nanoconstructs Achieve Higher Targeting Specificity of Immune Activation

Gene Regulation with Polyvalent Sirna-Nanoparticle Conjugates.

Polyvalent Immunostimulatory Nanoagents with Self‐Assembled CpG Oligonucleotide‐Conjugated Gold Nanoparticles

Enhanced Immunostimulatory Activity of a Cytosine-Phosphate-Guanosine Immunomodulator by the Assembly of Polymer DNA Wires and Spheres

Homotypic Targeting of Immunomodulatory Nanoparticles for Enhanced Peripheral and Central Immunity

Adjuvant-Loaded Spiky Gold Nanoparticles for Activation of Innate Immune Cells

Size-dependant gold nanoparticles attenuation of CpG DNA-induced TLR9 signaling by modulation of lysosome (89.42)

Amino Acid-Dependent Attenuation Of Toll-Like Receptor Signaling By Peptide-Gold Nanoparticle Hybrids

Tuning the Immunostimulation Properties of Cationic Lipid Nanocarriers for Nucleic Acid Delivery

Immunostimulation of Fibrous Nucleic Acid Nanoparticles Can be Modulated through Aptamer-Based Functional Moieties: Unveiling the Structure-Activity Relationship and Mechanistic Insights

Polyvalent nucleic acid nanostructures.

Polyvalent DNA nanoparticle conjugates stabilize nucleic acids.

Impact of Sequence Specificity of Spherical Nucleic Acids on Macrophage Activation in Vitro and in Vivo.